1 citations
,
January 1999 in “The European journal of contraception & reproductive health care” Valette® is an effective birth control pill that also reduces greasy hair and skin.
January 2022 in “Drugs of Today”
June 2024 in “Journal of Clinical Oncology” EGFR-TKIs can cause unexpected skin, nail, and hair issues.
October 2020 in “Journal of Pharmaceutical Sciences” Topical finasteride with EGCG or TA improves drug release and dermal uptake, potentially treating hair loss effectively.
October 2025 in “Clinical Chemistry” Juniperus communis extract enhances the effectiveness of oral cancer treatment when combined with chemotherapy.
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
March 2026 in “Pharmaceutics” Plant-derived nanovesicles show promise in cancer treatment but need standardized preparation.
52 citations
,
February 2003 in “Archives of dermatology” 9-cis-retinoic acid showed some effectiveness in treating AIDS-related Kaposi sarcoma but had significant side effects at higher doses.
79 citations
,
October 2003 in “PubMed” Overexpression of PKCepsilon leads to increased TNFalpha, promoting metastatic squamous cell carcinoma in mice.
6 citations
,
May 1986 in “Cancer Chemotherapy and Pharmacology” The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.
28 citations
,
September 2014 in “Journal of Veterinary Internal Medicine” VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.
25 citations
,
May 2018 in “Clinical & Translational Oncology” New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.
January 2013 in “대한피부과학회지” Gefitinib can cause rare scarring hair loss.
July 2024 in “Journal of Investigative Dermatology”
May 2017 in “Journal of The American Academy of Dermatology” An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
7 citations
,
September 2017 in “Pharmacoepidemiology and Drug Safety” The use of Diane-35 and its generics significantly decreased in the Netherlands.
68 citations
,
April 2014 in “Journal of Molecular Endocrinology” The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.
14 citations
,
January 2022 in “Evidence-based Complementary and Alternative Medicine” Cryptotanshinone may help treat postmenopausal osteoporosis and protect kidneys.
1 citations
,
December 2021 in “Tropical Journal of Pharmaceutical Research” Kanglaite injection with chemotherapy improves treatment and reduces side effects for advanced lung cancer.
April 2026 in “Phytotherapy Research” Licorice component glycyrrhizic acid may reduce skin side effects from cancer treatment.
9 citations
,
May 2019 in “Experimental Cell Research” HPV genes and estradiol increase a cancer-related signaling pathway, which may be targeted for cervical cancer treatment.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
June 2017 in “Journal of The American Academy of Dermatology” Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.
2 citations
,
March 2010 in “Acta Biochimica Polonica” Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
136 citations
,
April 2013 in “Clinical Cancer Research” The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.